Acylcarnitines are fatty acid metabolites that play important roles in many cellular energy
metabolism pathways. They have historically been used as important diagnostic markers for …

This review provides an update on the current clinical and preclinical understanding of
chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome …

Peripheral neuropathy is one of the most common side effects of chemotherapy, affecting up
to 60% of all cancer patients receiving chemotherapy. Moreover, paclitaxel induces …

The large Trp gene family encodes transient receptor potential (TRP) proteins that form
novel cation-selective ion channels. In mammals, 28 Trp channel genes have been …

Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose limiting side effect of
many commonly used chemotherapeutic agents, including platinum drugs, taxanes …

Chemotherapy induced peripheral neuropathy (CIPN) is a type of neuropathic pain that is a
major dose-limiting side-effect of potentially curative cancer chemotherapy treatment …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common, dose‐limiting side
effect of many chemotherapeutic agents. Although many therapies have been investigated …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a serious adverse side effect of
many chemotherapeutic agents, affecting> 60% of patients with cancer. Moreover, CIPN …

Cancer chemotherapeutics like paclitaxel and oxaliplatin produce a dose-limiting chronic
sensory peripheral neuropathy that is often accompanied by neuropathic pain. The cause of …

Paclitaxel is a first-line chemotherapeutic with the major dose-limiting side effect of painful
neuropathy. Previous preclinical studies indicate mitochondrial dysfunction and oxidative …